AstraZeneca Pharma India Limited has announced the upcoming launch of Breztri Aerosphere in January 2025. This innovative inhalation therapy combines Budesonide Ph. Eur 160 mcg, Glycopyrronium Ph. Eur 7.2 mcg, and Formoterol Fumarate Dihydrate Ph. Eur 5 mcg to address chronic obstructive pulmonary disease (COPD).
The medication is designed for the maintenance treatment of COPD, aiming to relieve symptoms and prevent exacerbations in adult patients. The drug received import and market permission in December 2023.
The introduction of Breztri Aerosphere reflects AstraZeneca’s commitment to improving respiratory care in India, offering a cutting-edge solution for COPD management.
TOPICS:
AstraZeneca Pharma